AI in Biotechnology Market: How Is Artificial Intelligence Reshaping the Future of Global Biotech Innovation in 2026-2035?

How Is North America Leading the Global AI in Biotechnology Market?

North America accounted for 50% of the global revenue in 2024, making it the undisputed leader in AI-enabled biotech solutions. This dominance is rooted in several structural advantages. The region is home to a highly developed pharmaceutical sector, robust computational infrastructure, and major AI-driven biotech companies. The U.S. has also implemented strong federal initiatives supporting AI-driven research, particularly in precision oncology, genomics, rare diseases, and clinical trial optimization.

Additionally, the U.S. boasts a thriving ecosystem of startups, venture capital firms, and innovation hubs. Powerful initiatives such as the National Cancer Institute's Childhood Cancer Data Initiative, a USD 500 million program, are fostering large-scale data collection and AI-driven discovery.

Canada is also emerging as a strong contributor. Nearly 87% of Canadian healthcare organizations now use AI in some form, reflecting rapid adoption across diagnostics, drug discovery, and genomics. The country’s federal AI programs and national innovation centers have supported hundreds of AI-focused biotech projects, further strengthening its position.

Together, the U.S. and Canada form a highly competitive AI-bioeconomy powered by academic institutions, research labs, cloud platform providers, CROs, and technology giants.

How Is Asia-Pacific Becoming the Fastest-Growing Region in AI-Driven Biotech Innovation?

Asia-Pacific is projected to grow at the fastest CAGR during the forecast period. Several countries across the region are actively integrating AI into research workflows, diagnostics, and advanced computational biology.

China is propelling growth through massive investments in AI infrastructure and health data systems. With centralized hospital data from 38,000+ healthcare institutions, China has created one of the world’s largest medical datasets, fueling next-generation drug discovery, genomics-based diagnostics, and clinical modeling.

India is following a similar growth trajectory. The IndiaAI Mission’s investment of ₹10,371 crore ($1.2 billion) aims to strengthen AI infrastructure, develop indigenous AI models, and accelerate research in biotechnology. India's new BioE3 Policy encourages sustainable biomanufacturing and establishes national bio-AI hubs, creating a strong foundation for AI integration in research, agriculture, and biopharma.

Japan, South Korea, Thailand, and Singapore are also investing in multi-omics research, computational labs, and AI-driven diagnostics, accelerating the region’s overall growth.

How Is Europe Strengthening Its Position Through Policy, Regulation, and Investment?

Europe is building an innovation-forward AI-enabled biotechnology ecosystem through large-scale investments, ethical frameworks, and collaborative research networks. The European Union has launched a €200 billion AI investment plan to accelerate infrastructure development, including high-performance computing hubs for biotech research.

The introduction of the Artificial Intelligence Act in August 2024 ensures safe, transparent, and ethical deployment of AI in healthcare and biotechnology. This regulatory stability is encouraging more companies to invest in AI-enabled R&D.

Countries like Germany are taking a leadership role. Germany’s €5.5 billion national AI strategy aims to integrate AI into 10% of its GDP by 2030. The creation of the Innovation Park Artificial Intelligence (IPAI), a large-scale industrial research campus, reflects the country’s commitment to advancing human-centered AI and computational biotech research.

Finland, Sweden, Norway, Italy, and France are also building AI factories and data centers supporting startups, academia, and biotech innovators.

Which Application Segment Is Driving the Market’s Strongest Growth?

The dominant segment in 2024 was drug discovery and lead generation, accounting for 36% of total revenue. This dominance is the result of widespread adoption of AI-driven platforms that reduce discovery timelines by up to 30%. AI algorithms streamline target identification, molecule screening, binding prediction, and early-stage modeling, enabling pharmaceutical companies to accelerate R&D pipelines.

This segment is expected to maintain its leadership as biopharma companies continue investing heavily in computational drug discovery.

However, the agriculture and industrial biotechnology segment is emerging as the fastest-growing category. With rising interest in biofertilizers, engineered enzymes, sustainable biomanufacturing, and climate-resilient crops, this segment is attracting investments exceeding USD 5 billion. Governments worldwide are encouraging the adoption of bio-based technologies and eco-friendly agricultural systems powered by AI-driven research and modelling.

Why Are Classical Machine Learning and Deep Learning Models Still Dominating the Market?

Although generative AI is growing rapidly, classical ML and deep learning models continue to dominate with 30% revenue share in 2024. Their widespread adoption across predictive analytics, molecular modeling, and biomarker discovery ensures their continued relevance.

Over 100 AI-driven drug discovery platforms currently rely on these models. Coupled with global investments of USD 3.5 billion in AI-based R&D, classical ML and deep learning remain foundational technologies for biotech research, powering tasks such as:

• toxicity prediction

• drug-target interaction modeling

• protein structure interpretation

• omics data classification

Generative AI will grow faster in the coming decade, but classical machine learning remains the backbone of most deployed systems.

Why Are SaaS and Cloud AI Platforms Leading the Commercial Model Segment?

In 2024, SaaS and cloud AI platforms dominated with a 48% revenue share, driven by their scalability, flexibility, and cost efficiency. Biotech firms prefer cloud-based AI platforms because they offer immediate access to high-performance computing and collaborative workflows without requiring large infrastructure investments.

These platforms enable seamless integration with existing pipelines, real-time data sharing across global teams, and on-demand scaling during complex simulations or large dataset processing.

Cloud-based AI solutions also support:

• automated lab workflows

• in-silico experiments

• multi-user collaboration

• rapid deployment of new models

As a result, the SaaS model is expected to remain the fastest-growing segment during the forecast period.